title: Direct oral anticoagulants (DOACs) versus "new" oral anticoagulants (NOACs)?
authors.affiliation: Unilabs Coagulation Laboratory and Center for Perioperative Thrombosis and Hemostasis Zurich, Switzerland. Electronic address: lars.asmis@hin.ch.
authors.forename: Lars M
authors.initials: LM
authors.lastname: Asmis
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines / Q000627:therapeutic use; D006801:Humans; D008958:Models, Molecular; D009025:Morpholines / Q000627:therapeutic use; D000069552:Rivaroxaban; D009626:Terminology as Topic; D013876:Thiophenes / Q000627:therapeutic use; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D009025:Morpholines; D013876:Thiophenes; D014812:Vitamin K; C426686:ximelagatran; D000069552:Rivaroxaban